- Home
- SYBT vs PVLA Comparison
SYBT vs PVLA Comparison
Compare SYBT & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYBT | PVLA |
|---|---|---|
| Founded | 1904 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | SYBT | PVLA |
|---|---|---|
| Price | $72.39 | $128.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $76.00 | ★ $171.87 |
| AVG Volume (30 Days) | 137.9K | ★ 181.8K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 22.11 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | ★ $23,406,000.00 | N/A |
| Revenue This Year | $17.31 | N/A |
| Revenue Next Year | $9.32 | $104,350.18 |
| P/E Ratio | $14.95 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $61.51 | $20.20 |
| 52 Week High | $83.83 | $151.18 |
Technical Indicators
Market Signals| Indicator | SYBT | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 54.28 |
| Support Level | $72.29 | $108.99 |
| Resistance Level | $73.79 | $135.23 |
| Average True Range (ATR) | 1.82 | 6.36 |
| MACD | -0.06 | -0.61 |
| Stochastic Oscillator | 64.64 | 46.82 |
Price Performance
Historical ComparisonAbout SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.